Ultrasonic flow probes have been used to optimize biventricular pacing immediately after cardiopulmonary bypass, improving cardiac output (CO) by 10%; however, flow probes must be removed with chest closure. The PulseCO system (LiDCO Limited, Cambridge, UK) may extend optimization into the postoperative period, but controlled validations have not been reported. Six anesthetized pigs were instrumented for right heart bypass. Flow was varied from 3 to 1 L/min and then back to 3 in 0.5 L/min increments for 60 second intervals. CO was measured by ultrasonic flow probe on the aorta and by PulseCO using a femoral arterial line. PulseCO and flow probe accurately measured CO (PulseCO Measurement of cardiac output (CO) is important experimentally and clinically as an indicator of ventricular function. Ultrasonic flow probes are reproducible and accurate, providing instantaneous flow velocity and a digital readout of CO. 1 Maximization of CO during biventricular pacing (BiVP) requires real time optimization of atrioventricular delay and right-left ventricular (V-V) delay on a patient to patient basis. Initial studies using ultrasonic flow probes to optimize temporary BiVP immediately after cardiopulmonary bypass have shown a 10% improvement in CO with optimization; however, the flow probes must be removed with chest closure. 2 To extend BiVP optimization into the postoperative period, a less invasive, accurate method of CO measurement is required. The PulseCO system (LiDCO Limited, Cambridge, UK) is capable of providing a beat to beat display of cardiac output through an autocorrelation algorithm from a nonlinear transformation of the input analog arterial pressure. 4, 5 The PulseCO algorithm uses the cardiac cycle length, or time between systolic pressure waves, to calculate heart rate (HR) and multiplies this by the derived nominal stroke volume to calculate CO. Studies have shown the reliability of the PulseCO system in the first 8 hours after cardiac surgery, but no controlled flow validations have been reported to our knowledge. 6 Accordingly, we performed a controlled flow validation to study the accuracy and limitations of the PulseCO system. 
Measurement of cardiac output (CO) is important experimentally and clinically as an indicator of ventricular function. Ultrasonic flow probes are reproducible and accurate, providing instantaneous flow velocity and a digital readout of CO. 1 Maximization of CO during biventricular pacing (BiVP) requires real time optimization of atrioventricular delay and right-left ventricular (V-V) delay on a patient to patient basis. Initial studies using ultrasonic flow probes to optimize temporary BiVP immediately after cardiopulmonary bypass have shown a 10% improvement in CO with optimization; however, the flow probes must be removed with chest closure. 2 To extend BiVP optimization into the postoperative period, a less invasive, accurate method of CO measurement is required. The PulseCO system (LiDCO Limited, Cambridge, UK) is capable of providing a beat to beat display of cardiac output through an autocorrelation algorithm from a nonlinear transformation of the input analog arterial pressure. 4, 5 The PulseCO algorithm uses the cardiac cycle length, or time between systolic pressure waves, to calculate heart rate (HR) and multiplies this by the derived nominal stroke volume to calculate CO. Studies have shown the reliability of the PulseCO system in the first 8 hours after cardiac surgery, but no controlled flow validations have been reported to our knowledge. 6 Accordingly, we performed a controlled flow validation to study the accuracy and limitations of the PulseCO system. 
Materials and Methods

All
Surgical Preparation
Six domestic pigs (40 -45 kg) were anesthetized using ketamine hydrochloride (20 mg/kg intramuscular), xylazine hydrochloride (0.5 mg/kg intramuscular), and atropine sulfate (2 mg/kg intramuscular). Pigs were intubated and mechanically ventilated, maintaining arterial blood gas values within physiologic norms. Anesthesia was maintained with inhalation isofluorine (1.5-2%) in oxygen. An 18 gauge angiocatheter was placed in an ear vein for an intravenous infusion of 0.9% saline. Electrocardiogram leads were attached to the limbs, and the left femoral artery was instrumented with an 18 gauge angiocatheter attached to a pressure transducer to measure arterial pressure. After median sternotomy and longitudinal pericardiotomy, a lidocaine bolus (3 mg/kg intravenously) was given and a lidocaine drip started at 50 g/kg/min to suppress arrhythmias. A 24 mm real time ultrasonic flow probe (Transonic Systems Inc., Ithaca, NY) was placed on the ascending aorta. Electrocardiogram, arterial pressure, and flow velocity tracings were sampled and transferred through a 16 channel analog to digital converter (MacLab, ADInstruments Inc, Milford, MA) to a personal computer (iMac, Apple Computer, Cupertino, CA). The PulseCO system was connected to the arterial pressure signal via a pressure monitor to measure CO.
Right Heart Bypass
Animals were then heparinized with 300 IU/kg intravenously and instrumented for right heart bypass (RHBP 32/40 dual stage venous cannula was placed in the right atrium via a purse string suture. Arterial inflow was established using a Sarns 5.2 mm right angle, metal tip cannula placed in the left atrium via a purse string suture. Both cannulae were connected in parallel to the occlusive roller pump bypass machine, which included a Medtronic AFFINITY NT oxygenator and a Medtronic reservoir (Medtronic, Inc., Minneapolis, MN). The bypass system was primed with 500 ml of Hextend and 1,000 ml of crystalloid. Additional heparin was given to achieve an activated clotting time of 480 seconds. Animals were then placed on bypass. A malleable vent catheter was placed in the pulmonary artery via a purse string suture to drain any blood from the pulmonary system, and the lungs were deflated. This preparation allowed for control of CO by controlling all but bronchial artery inflow into the left atrium. After stabilization, pump mediated flow was varied from 3 to 1 L/min and then back to 3 in 0.5 L/min increments for 60 second intervals. A temporary bipolar epicardial pacing wire was then placed on the right atrium. At a constant flow of 2 L/min, heart rate (HR) was increased 30 bpm over the sinus rate by overdrive atrial pacing. A phenylephrine infusion was started at 5 g/kg/min to increase mean arterial pressure (MAP) by 20%. The infusion was then turned off, and MAP was allowed to return to baseline. A nitroprusside infusion was subsequently started at 5 mcg/kg/min to decrease MAP by 20%. The infusion was then turned off, and MAP was allowed to return to baseline. Before each intervention, PulseCO was calibrated to the pump flow.
Bypass Pump Calibration
After data collection, the bypass pump was calibrated using a timed collection technique. The pump was configured to allow internal recirculation of blood with an outflow tube that remained clamped during recirculation. Blood was then circulated at 1.0 L/min. Once stabilized, the outflow tube was unclamped, and the time to collect 500 ml of blood in a graduated cylinder was measured three times and averaged. Collected blood was then returned to the bypass reservoir.
Data Analysis
The data obtained from the analog to digital converter were imported into MATLAB (The MathWorks, Inc., Natick, MA) and processed with custom software. Beat to beat CO from the flow probe, MAP from the femoral arterial pressure line, and HR were calculated by integrating the signals over each cardiac cycle. The PulseCO system gave beat to beat CO. The values of beats for each of the pump mediated flows or each of the interventions were then averaged. PulseCO stabilization was calculated as the time for PulseCO measurements to reach a steady value after pump mediated flow was decreased from 2.5 L/min to 2 L/min. These values were averaged for six animals.
Statistical Analysis
Averaged CO from PulseCO and the flow probe were compared with calibrated RHBP flow by linear regression. In addition, Bland-Altman analysis was used to assess agreement between calibrated RHBP flow and measurements by PulseCO. 7 The effect of each of the interventions upon PulseCO and flow probe measurements was assessed by paired student's t-test.
Results
Representative hemodynamics from a representative experiment during RHBP flow variation are presented in Figure 1 . Figure 5 presents the results of all other interventions. When HR was increased (120 Ϯ 6 to 151 Ϯ 6 bpm), PulseCO falsely indicated an 8% increase in CO (2.13 vs. 2.30 L/min, p ϭ 0.014). When MAP was increased (49 Ϯ 1 to 55 Ϯ 2 mm Hg), PulseCO falsely indicated a 16% increase in CO (2.13 vs. 2.47 L/min, p ϭ 0.014). When MAP was decreased (46 Ϯ 2 to 39 Ϯ 2 mm Hg), PulseCO falsely indicated a 16% decrease in CO (2.13 vs. 1.79 L/min, p ϭ 0.003). The accuracy of the ultrasonic flow probe was not affected by these interventions.
Discussion
Perioperative care of patients undergoing cardiac surgery includes monitoring of CO. BiVP optimization is accomplished through maximization of CO. Traditionally, CO is monitored with pulmonary artery (PA) catheters. However, these catheters are invasive, not continuous, and carry a small risk of significant complications, including infection, arrhythmia, and pneumothorax from central line insertion. Surgeons have thus sought a less invasive means of monitoring CO.
Literature dating back 30 years has suggested that CO could be calculated based upon the arterial pressure waveform. 8, 9 Arterial compliance, or pressure change per unit volume change, is not constant over a range of arterial pressures; however, the relationship between pressure and volume remains similar among different subjects. 10 This allows the use of the arterial pressure waveform and a defined relation with pressure to calculate changes in stroke volume for each cardiac cycle. The advantages of PulseCO are a real time readout of CO and avoiding PA catheterization and associated complications.
The present validation study showed good agreement between average PulseCO CO measurements and calibrated RHBP flow for all six pigs. However, it is important to note that after changes in pump mediated flow, PulseCO CO measurements took an average of 28 seconds to stabilize, which appeared to be a reflection of a need for stabilization of arterial pressure (Figure 6) . The flow probe, on the other hand, immediately reflected any changes in CO. The accuracy of PulseCO was also affected by changes in HR and vasoactive drugs.
PulseCO appears to be a useful tool for assessing acute changes in CO and can be used in patients with heart failure or artificial internal organs. For this reason, we believe it is suitably accurate and minimally invasive for real time optimization of BiVP in the postoperative period if its limitations are recognized. Correction factors or adjustments to the PulseCO autocorrelation algorithm may prove to be important in addressing these limitations. Effect of hemodynamic interventions on PulseCO™ cardiac output measurements. When heart rate was increased, PulseCO™ falsely indicated an increase in cardiac output. When mean arterial pressure was increased, PulseCO™ falsely indicated an increase in cardiac output. When mean arterial pressure was decreased, PulseCO™ falsely indicated a decrease in cardiac output. CO, cardiac output; HR, heart rate; MAP, mean arterial pressure. Figure 6 . Plot showing the period of stabilization for PulseCO™ cardiac output measurements (dark line) when right heart bypass flow was decreased from 2.5 L/min to 2 L/min in one pig. Also shown is the corresponding mean arterial pressure (gray line). CO, cardiac output; MAP, mean arterial pressure.
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